Biomedical subjects

S Salamanca

Publications and source records attributed to S Salamanca.

7 recordsLinked to original sources

PubMed1994

[Anomalous uterine bleeding in the perimenopause: fibromatosis, hyperplastic endometriopathy and GnRH analogs].

In the light of recent reports, the authors used GnRH analogues to treat 18 perimenopausal women with anomalous uterine bleeding, fibromatosis and endometrial hyperplasia. The aim of the study was to avoid the recurrence of anomalous bleeding, reduce hyperplastic endometriopathy and, having attained stable amenorrhea, avoid resorting to traditional surgical treatment. At the end of the study 9 women had reached the pre-established objective, 4 recommended regular menstruation, 2 reported an episode of metrorrhagia due to endometrial atrophy, and a further 2 suffered a recurrence of the initial problem and underwent hystero-annexiectomy. One patient interrupted the therapy due to the onset of arterial hypertension.

Drug Evaluation↗

PubMed1994

[HPV genital infections + CIN. The immunological patterns, loop electroablation and beta-interferon].

Sixteen patients with genital HPV associated with CIN were treated with electroablation using a diathermic loop and immunomodulation with human beta interferon. Changes in immunological, cyto-histological and clinical parameters were observed pre- and post-treatment. Thirteen cases showed an excellent response. Disease was persistent in three cases. The authors report an improvement, even if statistically non-significant, in some immune parameters and confirm the value of associating physical therapy with immunomodulating treatment.

Adult↗

PubMed1992

Estradiol modulation of the hyperphagia induced by the 5-HT1A agonist, 8-OH-DPAT.

Ovariectomized rats were primed with sesame oil or estradiol benzoate followed 48 h later by either sesame oil or progesterone. Four hours later, rats were treated with either saline or 0.25 mg/kg 8-hydroxy-2-9(di-n-propylamino)tetralin (8-OH-DPAT). Rats were allowed to eat for 4 h after this final treatment. Animals in all hormonal conditions showed hyperphagia following 8-OH-DPAT. However, the hyperphagia was significantly attenuated by pretreatment with estradiol benzoate. There was no effect of progesterone on the hyperphagic response. These results suggest that previous findings of an estrous cycle modulation of the hyperphagic response to 8-OH-DPAT arise from the modulatory effects of estradiol, and not progesterone, during the female reproductive cycle.

8-Hydroxy-2-(di-n-propylamino)tetralin↗

PubMed1991

Chlordecone (Kepone) on the night of proestrus inhibits female sexual behavior in CDF-344 rats.

The effect of the estrogen-like chlorinated pesticide chlordecone (Kepone) on sexual behavior was examined in proestrous rats following treatment with 25, 50, or 75 mg/kg chlordecone. In most animals, sexual behavior, both receptivity and proceptivity, was reduced within 60 min following the higher dosage of chlordecone. Reduced sexual receptivity occurred more slowly with 50 mg/kg chlordecone (usually within 180 min) and no reduction was seen following 25 mg/kg chlordecone. The reduced sexual behavior after chlordecone treatment preceded the onset of marked chlordecone-induced tremor. A group of rats treated with 75 mg/kg chlordecone was euthanized at the time that behavioral inhibition began to develop. The content of serotonin, norepinephrine, and their principal metabolites was determined by high-performance liquid chromatography of extracts of brain tissue of these animals. In hypothalamus, increases in serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) content, and a decrease in the level of norepinephrine (NE), were detected in chlordecone-treated rats relative to matched controls which received vehicle. The content of 5-HT was also increased in preoptic area of chlordecone-treated females. The content of the catecholamine metabolite, 3,4-dihydroxy-phenylacetic acid, was unaffected by chlordecone in either part of brain. These are the first observations of the parallel effects of chlordecone on receptive and proceptive behaviors, and on neurochemistry, in female rats; the results demonstrate short-latency effects of the pesticide treatment on the CNS events that mediate female reproductive behavior. Results of previous studies had led to the suggestion that chlordecone's inhibition of sexual behaviors resulted from its interaction with the intracellular estrogen receptor. However, the rapidity of the inhibition during the period of ongoing sexual behavior makes it unlikely that the inhibition is mediated by the pesticide's action at the intracellular estrogen receptor. Because of the importance of sexual behaviors to reproductive fitness, the current results indicate that nonsteroidal, behavioral mechanisms could contribute to chlordecone's neuroreproductive toxicity.

Analysis of Variance↗

PubMed1991

Gender and estrous cycle differences in the response to the 5-HT1A agonist 8-OH-DPAT.

The effects of the 5-HT1A agonist, 8-hydroxy-2-9(di-n-propylamino)tetralin (8-OH-DPAT) on eating behavior and on rectal temperature were examined in adult male rats and in diestrous, proestrous, and estrous female rats. The 5-HT1A agonist produced evidence of hyperphagia at some dose (0.125, 0.25, 0.5 and 1.0 mg/kg) in all groups examined. However, hyperphagia was most evident in diestrous females and least evident in proestrous and estrous rats. These findings are interpreted as an estrous cycle modulation of somatodendritic 5-HT1A autoreceptors. The hypothermic response to 8-OH-DPAT was present in all females and at all doses of 8-OH-DPAT (0.1, 0.25 and 0.5 mg/kg). These findings suggest that postsynaptic 5-HT1A sites involved in 8-OH-DPAT-induced hypothermia do not vary during the estrous cycle. However, males showed less hypothermia following 8-OH-DPAT than did females. The gender difference was evidenced primarily as a slower onset of hypothermia in males treated with the lower doses of the drug.

8-Hydroxy-2-(di-n-propylamino)tetralin↗

PubMed1990

[Oral galactose tolerance test in the study of glucose metabolism disorders in patients with liver disease].

Patients with chronic liver disease (CLD) may show an abnormal glucose tolerance test (GTT). On the other hand, it is debated whether diabetics may undergo abnormalities of liver function. The aim of our study was to see whether galactose tolerance test (GaTT) is a suitable complementary diagnostic tool in defining the glucose metabolism abnormalities characteristic of the two above mentioned clinical entities. Thirty-one patients with CLD, 16 adult diabetics and 12 healthy volunteers were considered. GTT with radioimmunoassay of plasmatic insulin (IRI) and oral GaTT were performed. CLD patients were divided into two groups: with IRI/glycemia greater than 0.4 or less than 0.4. On GaTT, galactosemia was significantly raised in CLD compared to diabetics and control. Further, a statistically significant difference was shown in the glycemic variations during GaTT between diabetics and both CLD groups. A significantly inverse ratio galactosemia/glycemia occurred during GaTT and showed a different pattern between diabetics and CLD patients with impaired insulin secretion. A careful study of galactosemia and glycemia variations during GaTT reliably defines the different patterns of glucose metabolism derangement in CLD with abnormal GTT and in diabetics.

Blood Glucose↗

PubMedDate not supplied

[Neoplasms with unknown primary location].

Neoplasms with unknown primary location (U.P.L.N.) represent an important chapter of oncological pathology which has not yet been completely defined regarding diagnostics, therapy and prognosis. U.P.L.N. recur in clinical practice in 0.5%-10% of cases and show equal sharing in both sexes: still mortality is high. This is in agreement with the biological behavior of U.P.L.N. which is that of a neoplastic illness, systemic from the onset and therefore immediately aggressive. Treatments commonly used only slightly alter the course of the disease. If the general state of the patients allows it, treatment must include every available therapeutical remedy (CHR, RDT, CHM) conveniently evaluated in every single case and preferably under the guidance of the apparent histotype and of the onset seat. The histotype of an U.P.L.N. sensibly affects the prognosis of the patient: there is an improvement in well differentiated and lodged forms and conversely, there is a sharp impairment with fast evolution in the less differentiated and variably metastasized forms. In our case-report, the U.P.L.N. rate has been 5.37% on 1786 cancer diagnoses from February 1980 until January 1988. In 65% of these cases, the histotype sustaining the pathology was represented by adenocarcinoma, in 21% by epidermoid carcinoma and in the remaining 14% by undifferentiated carcinoma. The clinical onset most frequently observed has involved the lymph nodes, followed by involvement of the serosa, bones, lungs and liver. Complex therapeutic treatments have not provided clear results, but the use of anthracyclines and cyclophosphamide seems promising. Finally, we suggest the use of immunomodulators (such as interferons, thymus hormone, lymphokines) in association with the classic chemotherapeutics.

Adenocarcinoma↗